Project R-16016

Positioning RA biomarkers as a stratification tool for second-line therapy (Research)

This project aims to evaluate the potential of anti-UH-RA.305/318/329 antibodies as predictive biomarkers for second-line therapy response in rheumatoid arthritis (RA). By analyzing serum samples from a clinically well-characterized cohort, the study will assess antibody reactivity in relation to treatment outcomes. The ultimate goal is to identify markers that can guide more personalized treatment strategies and improve outcomes for people living with RA. Furthermore, successful validation of these antibodies as predictive markers for second-line therapy response will strengthen their clinical utility and commercial attractiveness. This, in turn, will support future licensing opportunities and encourage strategic partnerships with industry stakeholders.

01 September 2025 - 31 August 2026